chr	start	end	ID	miRNA_name	methods	regulated	function description	PMID	year	title	drug	circulating	survival	num
NA	NA	NA	NA	hsa-let-7a	qRT-PCR,etc.	down	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	1
chr9	94175957	94176036	MI0000060	hsa-let-7a-1	qRT-PCR,etc.	up	let-7a* is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	2
chr11	122146522	122146593	MI0000061	hsa-let-7a-2	qRT-PCR,etc.	up	let-7a* is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	3
chr22	46112749	46112822	MI0000062	hsa-let-7a-3	qRT-PCR,etc.	up	let-7a* is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	4
chr22	46113686	46113768	MI0000063	hsa-let-7b	qRT-PCR,etc.	differential expression	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.	22821209	2012	Circulating microRNA Profiles Reflect the Presence of Breast Tumours but Not the Profiles of microRNAs Within the Tumours	0	1	0	5
chr9	94178834	94178920	MI0000065	hsa-let-7d	etc.	differential expression	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.	22081076	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	6
chr19	51692786	51692864	MI0000066	hsa-let-7e	Western Blot,qRT-PCR,ChIP,etc.	differential expression	Jumonji/Arid1 B (JARID1B) promotes breast tumor cell cycle progression through epigenetic repression of micro RNA let-7e.	21969366	2011	Jumonji/ARID1 B (JARID1B) Protein Promotes Breast Tumor Cell Cycle Progression Through Epigenetic Repression of microRNA let-7e	0	0	0	7
NA	NA	NA	NA	hsa-let-7f	etc.	down	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.	24104964	2013	MicroRNA-based Molecular Classification of non-BRCA1/2 Hereditary Breast Tumours	0	0	0	8
chr9	94176347	94176433	MI0000067	hsa-let-7f-1	etc.	differential expression	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.	22081076	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	9
chrX	53557192	53557274	MI0000068	hsa-let-7f-2	etc.	differential expression	LIN28: A regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer.	22081076	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	10
chr12	62603686	62603769	MI0000434	hsa-let-7i	etc.	down	Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.	24104964	2013	MicroRNA-based Molecular Classification of non-BRCA1/2 Hereditary Breast Tumours	0	0	0	11
NA	NA	NA	NA	hsa-miR-10	qRT-PCR,etc.	up	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	12
chr11	122152229	122152308	MI0000102	hsa-miR-100	qRT-PCR,microarray,etc.	differential expression	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.	25722304	2015	Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments	0	1	0	13
NA	NA	NA	NA	hsa-miR-101	Western blot,Luciferase assay,	differential expression	miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.	25059472	2014	miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.	0	0	1	14
chr1	65058434	65058508	MI0000103	hsa-miR-101-1	etc.	up	Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer.	24475105	2014	Genetic Variations in the Flanking Regions of miR-101-2 Are Associated With Increased Risk of Breast Cancer	0	0	1	15
chr9	4850297	4850375	MI0000739	hsa-miR-101-2	etc.	up	Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer.	24475105	2014	Genetic Variations in the Flanking Regions of miR-101-2 Are Associated With Increased Risk of Breast Cancer	0	0	1	16
chr5	168560896	168560973	MI0000109	hsa-miR-103a-1	qRT-PCR,etc.	differential expression	significantly increased in serum of breast cancer patients.	22387599	2012	Analysis of Serum Genome-Wide microRNAs for Breast Cancer Detection	0	0	0	17
chr7	100093993	100094074	MI0000734	hsa-miR-106b	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	18
chr10	89592747	89592827	MI0000114	hsa-miR-107	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	19
chr10	89592747	89592827	MI0000114	hsa-miR-107	qRT-PCR,etc.	differential expression	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy	28128741	2018	MicroRNA in breast cancer: The association with BRCA1/2	0	0	0	20
chr17	48579838	48579947	MI0000266	hsa-miR-10a	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	21
chr2	176150303	176150412	MI0000267	hsa-miR-10b	etc.	down-regulated	Successful inhibition of tumor cell growth byRNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article wereview the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and aswell as both the benefits and limitations of experimental RNAi.	16466964	2006	RNA Interference in Cancer	0	0	0	22
chr2	176150303	176150412	MI0000267	hsa-miR-10b	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	23
chr2	176150303	176150412	MI0000267	hsa-miR-10b	qRT-PCR,etc.	differential expression	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.	28101798	2017	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers	0	0	0	24
chr20	62554306	62554376	MI0000651	hsa-miR-1-1	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	25
chr8	128049152	128049238	MI0006340	hsa-miR-1207	microarray,qRT-PCR,etc.	differential expression	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.	25047087	2014	MicroRNA Profile in Very Young Women With Breast Cancer	0	1	1	26
chr18	58451074	58451158	MI0000442	hsa-miR-122	qRT-PCR,etc.	differential expression	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.	22400902	2012	De Novo Sequencing of Circulating miRNAs Identifies Novel Markers Predicting Clinical Outcome of Locally Advanced Breast Cancer	0	0	0	27
chr16	2090195	2090284	MI0006311	hsa-miR-1225	microarray,Western blot,etc.	down	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.	25961594	2015	MicroRNA Networks Regulated by All-Trans Retinoic Acid and Lapatinib Control the Growth, Survival and Motility of Breast Cancer Cells	0	0	1	28
chr12	57194504	57194576	MI0006318	hsa-miR-1228	microarray,qRT-PCR,etc.	differential expression	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.	25047087	2014	MicroRNA Profile in Very Young Women With Breast Cancer	0	1	1	29
NA	NA	NA	NA	hsa-miR-124	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	30
chr8	9903388	9903472	MI0000443	hsa-miR-124-1	qRT-PCR,etc.	differential expression	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.	21318219	2011	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer	0	0	1	31
chr8	64379149	64379257	MI0000444	hsa-miR-124-2	qRT-PCR,etc.	differential expression	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.	21318219	2011	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP2 gene confer differential predisposition to breast cancer	0	0	1	32
chr20	63178500	63178586	MI0000445	hsa-miR-124-3	qRT-PCR,etc.	differential expression	Genetic variants (SNP rs1042538 A/T) at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.	21318219	2011	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP3 gene confer differential predisposition to breast cancer	0	0	1	33
chr2	176600980	176601052	MI0006381	hsa-miR-1246	qRT-PCR,etc.	up	In conclusion, our results indicate that a diagnostic indexprepared using a combination of miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p measured from serum canbe used to detect breast cancer in the early stages and to differ-entiate breast cancer from pancreas?biliary tract?prostate benigndiseases or other cancers. We hope that such a diagnostic indexwill be implemented to help detect breast cancer in the earlystages, thus improving the curability of breast cancer in thefuture.	26749252	2015	Novel Combination of Serum microRNA for Detecting Breast Cancer in the Early Stage	0	1	0	34
chr3	186786672	186786777	MI0006383	hsa-miR-1248	microarray,qRT-PCR,etc.	differential expression	we identified miRNA expression signatures predictive of BRCA1/2 mutation status in routinely available FFPE breast tumor samples, which may be useful to complement current patient selection criteria for gene testing by identifying individuals with high likelihood of being BRCA1/2 mutation carriers.	24917463	2014	MicroRNA Expression Signatures for the Prediction of BRCA1/2 Mutation-Associated Hereditary Breast Cancer in Paraffin-Embedded Formalin-Fixed Breast Tumors	0	0	0	35
NA	NA	NA	NA	hsa-miR-124a-1	qRT-PCR,etc.	up	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.	24375250	2014	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 Genes Correlates With Aggressive and Advanced Breast Cancer Disease	0	0	0	36
NA	NA	NA	NA	hsa-miR-124a-2	qRT-PCR,etc.	up	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.	24375250	2014	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 Genes Correlates With Aggressive and Advanced Breast Cancer Disease	0	0	0	37
NA	NA	NA	NA	hsa-miR-124a-3	qRT-PCR,etc.	up	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.	24375250	2014	Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 Genes Correlates With Aggressive and Advanced Breast Cancer Disease	0	0	0	38
NA	NA	NA	NA	hsa-miR-125b	microarray,qRT-PCR,etc.	down	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.	26056355	2015	Tumor microRNA Expression Profiling Identifies Circulating microRNAs for Early Breast Cancer Detection	0	1	0	39
NA	NA	NA	NA	hsa-miR-125b	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	40
chr11	122099757	122099844	MI0000446	hsa-miR-125b-1	etc.	down-regulated	Successful inhibition of tumor cell growth byRNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article wereview the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and aswell as both the benefits and limitations of experimental RNAi.	16466964	2006	RNA Interference in Cancer	0	0	0	41
chr21	16590237	16590325	MI0000470	hsa-miR-125b-2	etc.	down-regulated	Successful inhibition of tumor cell growth byRNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article wereview the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and aswell as both the benefits and limitations of experimental RNAi.	16466964	2006	RNA Interference in Cancer	0	0	0	42
chr9	136670602	136670686	MI0000471	hsa-miR-126	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	43
chr14	100882979	100883075	MI0000472	hsa-miR-127	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	44
NA	NA	NA	NA	hsa-miR-1274b	qRT-PCR,microarray,etc.	differential expression	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.	25722304	2015	Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments	0	1	0	45
chr6	33999972	34000051	MI0006415	hsa-miR-1275	microarray,qRT-PCR,etc.	differential expression	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.	25047087	2014	MicroRNA Profile in Very Young Women With Breast Cancer	0	1	1	46
NA	NA	NA	NA	hsa-miR-128b	etc.	differential expression	Aside from the previously identified miR-200 family, these include the miR-15/16 (miR-16, miR-15b) and miR-103/107 (miR-103, miR-107) families as well as miR-145, miR-335, and miR-128b.	22908280	2012	Circulating microRNA Profiles Reflect the Presence of Breast Tumours but Not the Profiles of microRNAs Within the Tumours	0	1	1	47
chr10	103394253	103394401	MI0006444	hsa-miR-1307	qRT-PCR,etc.	up	In conclusion, our results indicate that a diagnostic indexprepared using a combination of miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p measured from serum canbe used to detect breast cancer in the early stages and to differ-entiate breast cancer from pancreas?biliary tract?prostate benigndiseases or other cancers. We hope that such a diagnostic indexwill be implemented to help detect breast cancer in the earlystages, thus improving the curability of breast cancer in thefuture.	26749252	2015	Novel Combination of Serum microRNA for Detecting Breast Cancer in the Early Stage	0	1	0	48
chr11	57641198	57641286	MI0000448	hsa-miR-130a	qRT-PCR,etc.	up	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	26033453	2015	Aberrant Plasma Levels of Circulating miR-16, miR-107, miR-130a and miR-146a Are Associated With Lymph Node Metastasis and Receptor Status of Breast Cancer Patients	0	1	0	49
chr19	53671968	53672040	MI0003786	hsa-miR-1323	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	50
chr20	62564912	62565013	MI0000451	hsa-miR-133a-2	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	51
chr1	205448302	205448398	MI0000810	hsa-miR-135b	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	52
chr11	72615063	72615130	MI0000261	hsa-miR-139	etc.	differential expression	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.	24866763	2014	Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition	0	1	1	53
chr16	69933081	69933180	MI0000456	hsa-miR-140	qRT-PCR,etc.	differential expression	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	54
chr12	6964097	6964191	MI0000457	hsa-miR-141	Microarray,etc.	differential expression	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).	22952344	2012	Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer 	0	0	0	55
chr17	28861533	28861618	MI0000460	hsa-miR-144	qRT-PCR,etc.	up	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.	26124344	2015	microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR	0	1	1	56
chr5	149430646	149430733	MI0000461	hsa-miR-145	etc.	down-regulated	Successful inhibition of tumor cell growth byRNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article wereview the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and aswell as both the benefits and limitations of experimental RNAi.	16466964	2006	RNA Interference in Cancer	0	0	0	57
chr5	149430646	149430733	MI0000461	hsa-miR-145	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	58
NA	NA	NA	NA	hsa-miR-146	qRT-PCR,etc.	differential expression	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	59
NA	NA	NA	NA	hsa-miR-146	qRT-PCR,etc.	differential expression	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy	28128741	2018	MicroRNA in breast cancer: The association with BRCA1/2	0	0	0	60
chr15	96333261	96333307	MI0007074	hsa-miR-1469	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	61
chr5	160485352	160485450	MI0000477	hsa-miR-146a	qRT-PCR,etc.	up	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	26033453	2015	Aberrant Plasma Levels of Circulating miR-16, miR-107, miR-130a and miR-146a Are Associated With Lymph Node Metastasis and Receptor Status of Breast Cancer Patients	0	1	0	62
chr5	160485352	160485450	MI0000477	hsa-miR-146a	qRT-PCR,etc.	up	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.	28101798	2017	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers	0	0	0	63
chr10	102436512	102436584	MI0003129	hsa-miR-146b	etc.	Down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	0	0	0	64
chr10	102436512	102436584	MI0003129	hsa-miR-146b	qRT-PCR,etc.	up	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	65
chr2	231892242	231892298	MI0007076	hsa-miR-1471	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	66
chr7	25949919	25949986	MI0000253	hsa-miR-148a	qRT-PCR,etc.	differential expression	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.	25004125	2014	Alterations in Circulating miRNA Levels Following Early-Stage Estrogen Receptor-Positive Breast Cancer Resection in Post-Menopausal Women	0	1	0	67
chr12	54337216	54337314	MI0000811	hsa-miR-148b	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	68
NA	NA	NA	NA	hsa-miR-15	qRT-PCR,etc.	differential expression	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy	28128741	2018	MicroRNA in breast cancer: The association with BRCA1/2	0	0	0	69
NA	NA	NA	NA	hsa-miR-153	qRT-PCR,etc.	differential expression	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.	28101798	2017	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers	0	0	0	70
chr7	157574336	157574422	MI0000464	hsa-miR-153-2	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	71
chr13	50049119	50049201	MI0000069	hsa-miR-15a	etc.	Down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	0	0	0	72
chr13	50049119	50049201	MI0000069	hsa-miR-15a	qRT-PCR,etc.	up	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	73
chr13	50049119	50049201	MI0000069	hsa-miR-15a	qRT-PCR,etc.	down	Fatty acid synthase is a primary target of MiR-15a and MiR-16-1 in breast cancer.	27713175	2015	miRNA Expression Patterns in Normal Breast Tissue and Invasive Breast Cancers of BRCA1 and BRCA2 Germ-Line Mutation Carriers	1	0	0	74
NA	NA	NA	NA	hsa-miR-16	qRT-PCR,etc.	up	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	26033453	2015	Aberrant Plasma Levels of Circulating miR-16, miR-107, miR-130a and miR-146a Are Associated With Lymph Node Metastasis and Receptor Status of Breast Cancer Patients	0	1	0	75
NA	NA	NA	NA	hsa-miR-16	qRT-PCR,etc.	up	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	76
chr13	50048973	50049061	MI0000070	hsa-miR-16-1	qRT-PCR,etc.	differential expression	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.	22298638	2012	Serum microRNA Profiling and Breast Cancer Risk: The Use of miR-484/191 as Endogenous Controls	0	0	1	77
chr3	160404745	160404825	MI0000115	hsa-miR-16-2	qRT-PCR,etc.	differential expression	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.	22298638	2012	Serum microRNA Profiling and Breast Cancer Risk: The Use of miR-484/191 as Endogenous Controls	0	0	1	78
NA	NA	NA	NA	hsa-miR-181b	etc.	Down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	0	0	0	79
NA	NA	NA	NA	hsa-miR-181b	Microarray,etc.	up	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	80
chr7	129770383	129770492	MI0000272	hsa-miR-182	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	81
chr7	129770383	129770492	MI0000272	hsa-miR-182	qRT-PCR,etc.	differential expression	miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy	28128741	2018	MicroRNA in breast cancer: The association with BRCA1/2	0	0	0	82
chr7	129774905	129775014	MI0000273	hsa-miR-183	qRT-PCR,etc.	up	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.	26124344	2015	microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR	0	1	1	83
chr13	91350751	91350821	MI0000072	hsa-miR-18a	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	84
chrX	134170041	134170111	MI0001518	hsa-miR-18b	qRT-PCR,etc.	differential expression	Potential biomarker microRNAs were identified, including let-7b, let-7g and miR-18b, with higher circulating levels associated with tumours.	22821209	2012	Circulating microRNA Profiles Reflect the Presence of Breast Tumours but Not the Profiles of microRNAs Within the Tumours	0	1	0	85
chr10	21496562	21496641	MI0008336	hsa-miR-1915	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	86
NA	NA	NA	NA	hsa-miR-193	microarray,Western blot,etc.	down	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.	25961594	2015	MicroRNA Networks Regulated by All-Trans Retinoic Acid and Lapatinib Control the Growth, Survival and Motility of Breast Cancer Cells	0	0	1	87
chr17	31559996	31560083	MI0000487	hsa-miR-193a	qRT-PCR,etc.	up	miR-193a-3p is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	88
chr1	220118157	220118241	MI0000488	hsa-miR-194-1	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	89
chr11	64891355	64891439	MI0000732	hsa-miR-194-2	Microarray,qRT-PCR,Luciferase Assay,etc.	differential expression	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer.	22829924	2012	Modulation of MicroRNA-194 and Cell Migration by HER2-targeting Trastuzumab in Breast Cancer	0	0	0	90
chr7	27169480	27169563	MI0001150	hsa-miR-196b	qRT-PCR,etc.	differential expression	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer.	25451164	2014	miRNA Expression Patterns in Chemoresistant Breast Cancer Tissues	0	1	1	91
chr3	120395668	120395729	MI0000240	hsa-miR-198	microarray,qRT-PCR,etc.	differential expression	Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers	26152113	2015	Comparative microRNA Profiling of Sporadic and BRCA1 Associated Basal-Like Breast Cancers	0	0	0	92
NA	NA	NA	NA	hsa-miR-199a	qRT-PCR,etc.	down	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.	26476723	2015	A Circulating miRNA Signature as a Diagnostic Biomarker for Non-Invasive Early Detection of Breast Cancer	0	1	0	93
chr19	10817426	10817496	MI0000242	hsa-miR-199a-1	etc.	down	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells	21317930	2011	Regulation of Axl Receptor Tyrosine Kinase Expression by miR-34a and miR-199a/b in Solid Cancer	1	0	1	94
chr1	172144535	172144644	MI0000281	hsa-miR-199a-2	etc.	down	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells	21317930	2011	Regulation of Axl Receptor Tyrosine Kinase Expression by miR-34a and miR-199a/b in Solid Cancer	1	0	1	95
chr9	128244721	128244830	MI0000282	hsa-miR-199b	etc.	down	Axl receptor expression can be regulated by miR-34a and miR-199a/b, which are suppressed by promoter methylation in solid cancer cells	21317930	2011	Regulation of Axl Receptor Tyrosine Kinase Expression by miR-34a and miR-199a/b in Solid Cancer	1	0	1	96
chr13	91350891	91350972	MI0000073	hsa-miR-19a	etc.	Down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	0	0	0	97
chr13	91350891	91350972	MI0000073	hsa-miR-19a	qRT-PCR,etc.	down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	98
NA	NA	NA	NA	hsa-miR-19b	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	99
NA	NA	NA	NA	hsa-miR-19b	qRT-PCR,etc.	down	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	100
chr13	91351192	91351278	MI0000074	hsa-miR-19b-1	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	101
chr1	1167863	1167952	MI0000737	hsa-miR-200a	Microarray,etc.	differential expression	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).	22952344	2012	Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer 	0	0	0	102
chr1	1167863	1167952	MI0000737	hsa-miR-200a	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	103
chr1	1167104	1167198	MI0000342	hsa-miR-200b	Microarray,etc.	differential expression	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).	22952344	2012	Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer 	0	0	0	104
chr10	133247511	133247620	MI0003130	hsa-miR-202	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	105
NA	NA	NA	NA	hsa-miR-203	Microarray,etc.	differential expression	CTC (circulating tumour cells)-positive had significantly higher levels of miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375 and miR-801 than CTC-negative MBC and controls (P < 0.00001), while miR-768-3p was present in lower amounts in MBC (metastatic breast cancer) cases (P < 0.05).	22952344	2012	Circulating microRNAs as Surrogate Markers for Circulating Tumour Cells and Prognostic Markers in Metastatic Breast Cancer 	0	0	0	106
chr9	70809975	70810084	MI0000284	hsa-miR-204	qRT-PCR,Luciferase Assays,etc.	differential expression	Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF- signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2).	22629385	2012	Identification of microRNAs Inhibiting TGF--induced IL-11 Production in Bone Metastatic Breast Cancer Cells	1	1	0	107
chr13	91351065	91351135	MI0000076	hsa-miR-20a	microarray,qRT-PCR,etc.	up	miR-20a: increased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	108
chrX	134169809	134169877	MI0001519	hsa-miR-20b	microarray,qRT-PCR,etc.	up	miR-20b: increased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	109
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,etc.	down	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer	23052693	2013	Circulating microRNA-92a and microRNA-21 as Novel Minimally Invasive Biomarkers for Primary Breast Cancer	0	1	1	110
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,Microarray,etc.	down	In summary, we have presented, for the first time, a luminal mammary cancer progression-associated miRNA profile and have shown that CR prevents the dysregulation of one of thesemiRNA, miR-200a. Further, we have shown that CR greatly reduces tumor initiation andgrowth, a protective effect that can be explained, at least in part, through CRs normalization ofmiR-200a expression and resultant inhibition of cellular proliferation. These findings deepenour understanding of the dysregulation of miRNA throughout cancer progression and suggestthat miR-200a may be a novel intervention target for mimicking the suppressive effects of CRon mammary tumor development and growth.	27433802	2016	Stage-Specific MicroRNAs and Their Role in the Anticancer Effects of Calorie Restriction in a Rat Model of ER-Positive Luminal Breast Cancer	0	0	1	111
chr1	220117853	220117962	MI0000291	hsa-miR-215	etc.	differential expression	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls	22353773	2012	Expression profiling of cancerous and normalbreast tissues identifies microRNAs that aredifferentially expressed in serum from patientswith (metastatic) breast cancer and healthyvolunteers	0	1	0	112
chr4	20528275	20528384	MI0000294	hsa-miR-218-1	Luciferase assays,qRT-PCR,Western blot,ChIP,etc.	differential expression	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.	22705304	2012	miR-7 and miR-218 Epigenetically Control Tumor Suppressor Genes RASSF1A and Claudin-6 by Targeting HoxB3 in Breast Cancer	0	0	0	113
chr5	168768146	168768255	MI0000295	hsa-miR-218-2	Luciferase assays,qRT-PCR,Western blot,ChIP,etc.	differential expression	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.	22705304	2012	miR-7 and miR-218 Epigenetically Control Tumor Suppressor Genes RASSF1A and Claudin-6 by Targeting HoxB3 in Breast Cancer	0	0	0	114
NA	NA	NA	NA	hsa-miR-219-1	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	115
chrX	45746157	45746266	MI0000298	hsa-miR-221	etc.	differential expression	The expression level of miR-221 was significantly associated with hormone receptor (HR) status (p = 0.008). Patients with higher plasma miR-221 levels tended to be HR-negative. Patients with different miR-221 levels had significant differences in the overall response rate (p = 0.044) but not in the pathologic complete response rate (p = 0.477).	22156446	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	116
chrX	45747015	45747124	MI0000299	hsa-miR-222	microarray,qRT-PCR,etc.	down	miR-222: decreased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	117
chrX	66018870	66018979	MI0000300	hsa-miR-223	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	118
chr2	207109987	207110073	MI0015873	hsa-miR-2355	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	119
chr19	13836587	13836659	MI0000079	hsa-miR-23a	qRT-PCR,etc.	differential expression	significantly increased in serum of breast cancer patients.	22387599	2012	Analysis of Serum Genome-Wide microRNAs for Breast Cancer Detection	0	0	0	120
chr9	95085208	95085304	MI0000439	hsa-miR-23b	qRT-PCR,etc.	differential expression	significantly increased in serum of breast cancer patients.	22387599	2012	Analysis of Serum Genome-Wide microRNAs for Breast Cancer Detection	0	0	0	121
chr9	95086021	95086088	MI0000080	hsa-miR-24-1	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	122
chr19	13836287	13836359	MI0000081	hsa-miR-24-2	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	123
chr7	100093560	100093643	MI0000082	hsa-miR-25	qRT-PCR,etc.	differential expression	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.	22298638	2012	Serum microRNA Profiling and Breast Cancer Risk: The Use of miR-484/191 as Endogenous Controls	0	0	1	124
NA	NA	NA	NA	hsa-miR-26a	qRT-PCR,etc.	differential expression	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.	28101798	2017	miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers	0	0	0	125
chr3	37969404	37969480	MI0000083	hsa-miR-26a-1	qRT-PCR,etc.	down	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.	22094936	2012	High miR-26a and Low CDC2 Levels Associate With Decreased EZH2 Expression and With Favorable Outcome on Tamoxifen in Metastatic Breast Cancer	0	0	0	126
chr12	57824609	57824692	MI0000750	hsa-miR-26a-2	qRT-PCR,etc.	down	High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.	22094936	2012	High miR-26a and Low CDC2 Levels Associate With Decreased EZH2 Expression and With Favorable Outcome on Tamoxifen in Metastatic Breast Cancer	0	0	0	127
chr20	58817615	58817694	MI0000747	hsa-miR-296	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	128
chr14	101023794	101023856	MI0000744	hsa-miR-299	etc.	differential expression	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls	22353773	2012	Expression profiling of cancerous and normalbreast tissues identifies microRNAs that aredifferentially expressed in serum from patientswith (metastatic) breast cancer and healthyvolunteers	0	1	0	129
chr7	130876747	130876810	MI0000087	hsa-miR-29a	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	130
chr1	207801852	207801939	MI0000735	hsa-miR-29c	qRT-PCR,etc.	down	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.	26476723	2015	A Circulating miRNA Signature as a Diagnostic Biomarker for Non-Invasive Early Detection of Breast Cancer	0	1	0	131
chr17	59151136	59151221	MI0000745	hsa-miR-301a	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	132
chr4	112648183	112648251	MI0000738	hsa-miR-302a	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	133
chr4	112648485	112648557	MI0000772	hsa-miR-302b	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	134
chr4	112648363	112648430	MI0000773	hsa-miR-302c	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	135
chr4	112648004	112648071	MI0000774	hsa-miR-302d	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	136
chr8	134800520	134800607	MI0000441	hsa-miR-30b	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	137
chr8	134804876	134804945	MI0000255	hsa-miR-30d	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	138
chr2	206783234	206783308	MI0014147	hsa-miR-3130-1	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	139
chr2	206783234	206783308	MI0014148	hsa-miR-3130-2	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	140
chr17	81451104	81451188	MI0014229	hsa-miR-3186	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	141
chr20	63238779	63238842	MI0014241	hsa-miR-3196	microarray,qRT-PCR,etc.	differential expression	The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.	25047087	2014	MicroRNA Profile in Very Young Women With Breast Cancer	0	1	1	142
chr1	116671746	116671817	MI0003776	hsa-miR-320b-1	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	143
chr1	224257040	224257110	MI0003839	hsa-miR-320b-2	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	144
chr18	21683518	21683589	MI0003778	hsa-miR-320c-1	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	145
chr18	24321675	24321746	MI0008191	hsa-miR-320c-2	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	146
chr13	40727828	40727846	MIMAT0006764	hsa-miR-320d	etc.	differential expression	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.	24866763	2014	Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition	0	1	1	147
chr13	40727816	40727887	MI0008190	hsa-miR-320d-1	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	148
chrX	140926160	140926231	MI0008192	hsa-miR-320d-2	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	149
chr19	46709282	46709354	MI0014234	hsa-miR-320e	qRT-PCR,Western blot,etc.	differential expression	Expression of the Pten-miR-320-Ets2-regulated secretome distinguished human normal breast stroma from tumour stroma and robustly correlated with recurrence in breast cancer patients. This work reveals miR-320 as a critical component of the Pten tumour-suppressor axis that acts in stromal fibroblasts to reprogramme the tumour microenvironment and curtail tumour progression.	22179046	2011	Reprogramming of the Tumour Microenvironment by Stromal PTEN-regulated miR-320	0	0	1	150
chr17	7223297	7223379	MI0000813	hsa-miR-324	qRT-PCR,etc.	differential expression	Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls.	22298638	2012	Serum microRNA Profiling and Breast Cancer Risk: The Use of miR-484/191 as Endogenous Controls	0	0	1	151
chr7	130496111	130496204	MI0000816	hsa-miR-335	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	152
chr17	81125883	81125949	MI0000814	hsa-miR-338	qRT-PCR,etc.	differential expression	A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.	25004125	2014	Alterations in Circulating miRNA Levels Following Early-Stage Estrogen Receptor-Positive Breast Cancer Resection in Post-Menopausal Women	0	1	0	153
chr7	1022933	1023026	MI0000815	hsa-miR-339	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	154
chr1	9151668	9151777	MI0000268	hsa-miR-34a	qRT-PCR,etc.	up	up-regulation of miR181b, miR-34a, miR-16, miR-15a and miR-146b-5p, and down-regulation of miR-19a and miR-19b have been shown following the treatment of several breast cancer cell lines with curcumin	29189128	2018	Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer	1	1	0	155
chr21	8208500	8208520	MIMAT0018068	hsa-miR-3648	etc.	down	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.	26717565	2015	Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas	0	0	1	156
chr16	14309285	14309371	MI0000767	hsa-miR-365a	qRT-PCR,etc.	down	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.	21953071	2012	Hsa-miR-375 Is Differentially Expressed During Breast Lobular Neoplasia and Promotes Loss of Mammary Acinar Polarity	0	0	0	157
chr4	112647874	112647941	MI0000775	hsa-miR-367	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	158
chr14	100911139	100911213	MI0000778	hsa-miR-370	qRT-PCR,etc.	differential expression	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer.	25451164	2014	miRNA Expression Patterns in Chemoresistant Breast Cancer Tissues	0	1	1	159
chrX	74218547	74218618	MI0005566	hsa-miR-374b	microarray,qRT-PCR,etc.	differential expression	Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers	26152113	2015	Comparative microRNA Profiling of Sporadic and BRCA1 Associated Basal-Like Breast Cancers	0	0	0	160
chr2	219001645	219001708	MI0000783	hsa-miR-375	qRT-PCR,etc.	differential expression	Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease.miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients.	22400902	2012	De Novo Sequencing of Circulating miRNAs Identifies Novel Markers Predicting Clinical Outcome of Locally Advanced Breast Cancer	0	0	0	161
NA	NA	NA	NA	hsa-miR-376a	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	162
chr14	101039690	101039755	MI0000776	hsa-miR-376c	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	163
chr14	101062050	101062118	MI0000785	hsa-miR-377	etc.	down	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.	26717565	2015	Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas	0	0	1	164
chr14	101022066	101022132	MI0000787	hsa-miR-379	qRT-PCR,Luciferase Assays,etc.	differential expression	Gene expression analysis of miR-204 and miR-379-transfected cells indicated that these miRNAs downregulated the expression of several genes involved in TGF- signaling, including prostaglandin-endoperoxide synthase 2 (PTGS2).	22629385	2012	Identification of microRNAs Inhibiting TGF--induced IL-11 Production in Bone Metastatic Breast Cancer Cells	1	1	0	165
chr8	14853438	14853510	MI0000791	hsa-miR-383	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	166
chr3	79507887	79507969	MI0016430	hsa-miR-3923	qRT-PCR,etc.	up	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.	24846313	2014	MiRNA Expression in Breast Cancer Varieswith Lymph Node Metastasis and OtherClinicopathologic Features	0	0	0	167
chr14	101065300	101065378	MI0001735	hsa-miR-409	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	168
chr14	101023325	101023420	MI0003675	hsa-miR-411	etc.	differential expression	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls	22353773	2012	Expression profiling of cancerous and normalbreast tissues identifies microRNAs that aredifferentially expressed in serum from patientswith (metastatic) breast cancer and healthyvolunteers	0	1	0	169
chrX	74218377	74218461	MI0003685	hsa-miR-421	qRT-PCR,etc.	up	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.	24846313	2014	MiRNA Expression in Breast Cancer Varieswith Lymph Node Metastasis and OtherClinicopathologic Features	0	0	0	170
chr17	30117079	30117172	MI0001445	hsa-miR-423	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	171
chrX	134546614	134546711	MI0001446	hsa-miR-424	qRT-PCR,etc.	down	Our data demonstrate that the SdM-RT-PCR assay is an effective breast cancer profiling method that utilizes very small volumes and is compatible with Biobank.Furthermore, the identified 3-miRNA signature is a promising circulating biomarker for breast cancer diagnosis.	26476723	2015	A Circulating miRNA Signature as a Diagnostic Biomarker for Non-Invasive Early Detection of Breast Cancer	0	1	0	172
chr1	150551929	150552014	MI0015856	hsa-miR-4257	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	173
chr1	1169005	1169087	MI0001641	hsa-miR-429	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	174
chr13	99643059	99643149	MI0015836	hsa-miR-4306	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	175
chrX	134540341	134540431	MI0001652	hsa-miR-450a-1	qRT-PCR,etc.	down	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.	21953071	2012	Hsa-miR-375 Is Differentially Expressed During Breast Lobular Neoplasia and Promotes Loss of Mammary Acinar Polarity	0	0	0	176
chrX	134540508	134540607	MI0003187	hsa-miR-450a-2	qRT-PCR,etc.	down	The miRNA was down-regulated during lobular neoplasia progression compared to normal epithelium.	21953071	2012	Hsa-miR-375 Is Differentially Expressed During Breast Lobular Neoplasia and Promotes Loss of Mammary Acinar Polarity	0	0	0	177
NA	NA	NA	NA	hsa-miR-451	qRT-PCR,etc.	differential expression	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	178
chr17	28861369	28861440	MI0001729	hsa-miR-451a	qRT-PCR,etc.	up	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.	26124344	2015	microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR	0	1	1	179
chrX	151959628	151959712	MI0001733	hsa-miR-452	etc.	differential expression	miR-215, miR-299-5p, miR-411, and miR-452 are differentially expressed between serum samples from patients with cancer and serum samples from healthy controls	22353773	2012	Expression profiling of cancerous and normalbreast tissues identifies microRNAs that aredifferentially expressed in serum from patientswith (metastatic) breast cancer and healthyvolunteers	0	1	0	180
chr5	174751734	174751787	MI0017261	hsa-miR-4634	qRT-PCR,etc.	up	In conclusion, our results indicate that a diagnostic indexprepared using a combination of miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p measured from serum canbe used to detect breast cancer in the early stages and to differ-entiate breast cancer from pancreas?biliary tract?prostate benigndiseases or other cancers. We hope that such a diagnostic indexwill be implemented to help detect breast cancer in the earlystages, thus improving the curability of breast cancer in thefuture.	26749252	2015	Novel Combination of Serum microRNA for Detecting Breast Cancer in the Early Stage	0	1	0	181
chr17	39726495	39726561	MI0017365	hsa-miR-4728	qRT-PCR,etc.	differential expression	MiR-4728-3p had better ability in distinguishing patients with different status of HER2 than miR-4728-5p. And plasma miR-4728-3p might act as a non-invasive biomarker in predicting HER2 status.	26406406	2015	Hsa-miR-1 Suppresses Breast Cancer Development by Down-Regulating K-ras and Long Non-Coding RNA MALAT1	0	0	0	182
NA	NA	NA	NA	hsa-miR-486	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	183
chr1	177029363	177029445	MI0003123	hsa-miR-488	qRT-PCR,etc.	differential expression	copy number gain	16754881	2006	microRNAs exhibit high frequency genomicalterations in human cancer	0	0	0	184
chr17	7017911	7018022	MI0003138	hsa-miR-497	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	185
chrX	139924148	139924231	MI0003190	hsa-miR-505	microarray,qRT-PCR,etc.	down	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.	26056355	2015	Tumor microRNA Expression Profiling Identifies Circulating microRNAs for Early Breast Cancer Detection	0	1	0	186
chr19	53679003	53679085	MI0003144	hsa-miR-515-1	qRT-PCR,Luciferase reporter assay,Western blot,etc.	differential expression	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers	23549953	2013	PRECLINICAL STUDY Involvement of IGF-1R regulation by miR-515-5p modifies breastcancer risk among BRCA1 carriers	0	1	1	187
chr19	53685009	53685091	MI0003147	hsa-miR-515-2	qRT-PCR,Luciferase reporter assay,Western blot,etc.	differential expression	Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers	23549953	2013	PRECLINICAL STUDY Involvement of IGF-1R regulation by miR-515-5p modifies breastcancer risk among BRCA1 carriers	0	1	1	188
chr19	53736845	53736934	MI0003172	hsa-miR-516b-1	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	189
chr19	53725442	53725526	MI0003167	hsa-miR-516b-2	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	190
chr19	53690881	53690965	MI0003149	hsa-miR-520a	etc.	differential expression	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.	22158050	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	191
chr19	53707453	53707539	MI0003158	hsa-miR-520c	etc.	differential expression	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.	22158050	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	192
chr19	53720096	53720182	MI0003164	hsa-miR-520d	etc.	differential expression	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-beta signaling pathways.	22158050	2012	LIN28: A Regulator of Tumor-Suppressing Activity of let-7 microRNA in Human Breast Cancer	0	0	0	193
chr19	53706252	53706336	MI0003157	hsa-miR-526a-1	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	194
chr19	53726922	53726986	MI0003168	hsa-miR-526a-2	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	195
chrX	134541341	134541437	MI0003686	hsa-miR-542	qRT-PCR,etc.	up	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.	24846313	2014	MiRNA Expression in Breast Cancer Varieswith Lymph Node Metastasis and OtherClinicopathologic Features	0	0	0	196
chr4	173268160	173268233	MI0014164	hsa-miR-548t	etc.	down	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.	26717565	2015	Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas	0	0	1	197
chr3	44861888	44861981	MI0003570	hsa-miR-564	qRT-PCR,etc.	up	miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features.	24846313	2014	MiRNA Expression in Breast Cancer Varieswith Lymph Node Metastasis and OtherClinicopathologic Features	0	0	0	198
chr3	112112801	112112898	MI0003573	hsa-miR-567	etc.	differential expression	Our identified mRNAs and microRNAs were validated as prognostic factors of BC disease progression, and could potentially facilitate the implementation of assays for laboratory validation, due to their reduced number.	24866763	2014	Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition	0	1	1	199
chr3	195699401	195699497	MI0003577	hsa-miR-570	microarray,qRT-PCR, ChIP-Seq,etc.	differential expression	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.	20348243	2010	Estrogen Receptor Alpha Controls a Gene Network in Luminal-Like Breast Cancer Cells Comprising Multiple Transcription Factors and microRNAs	1	0	0	200
chr4	82753337	82753430	MI0003582	hsa-miR-575	microarray,Western blot,etc.	down	our study demonstrates that HIPK2-kinase and the PLCXD1-phospholipase-C are novel targets of miR-193a-5p/miR-210-3p and miR-575/miR-1225-5p, respectively.	25961594	2015	MicroRNA Networks Regulated by All-Trans Retinoic Acid and Lapatinib Control the Growth, Survival and Motility of Breast Cancer Cells	0	0	1	201
chr4	109488698	109488795	MI0003583	hsa-miR-576	qRT-PCR,etc.	differential expression	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer.	25451164	2014	miRNA Expression Patterns in Chemoresistant Breast Cancer Tissues	0	1	1	202
chr7	74191198	74191294	MI0003602	hsa-miR-590	microarray,qRT-PCR,etc.	differential expression	Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers	26152113	2015	Comparative microRNA Profiling of Sporadic and BRCA1 Associated Basal-Like Breast Cancers	0	0	0	203
chr12	80935736	80935833	MI0003632	hsa-miR-618	microarray,qRT-PCR, ChIP-Seq,etc.	differential expression	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.	20348243	2010	Estrogen Receptor Alpha Controls a Gene Network in Luminal-Like Breast Cancer Cells Comprising Multiple Transcription Factors and microRNAs	1	0	0	204
chr14	65471102	65471186	MI0003639	hsa-miR-625	qRT-PCR,etc.	up	miR-625* is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	205
NA	NA	NA	NA	hsa-miR-633b	etc.	down	Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.	26717565	2015	Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas	0	0	1	206
chrX	110055329	110055426	MI0003667	hsa-miR-652	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	207
chr12	112163258	112163321	MI0022708	hsa-miR-6861	qRT-PCR,etc.	up	In conclusion, our results indicate that a diagnostic indexprepared using a combination of miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p measured from serum canbe used to detect breast cancer in the early stages and to differ-entiate breast cancer from pancreas?biliary tract?prostate benigndiseases or other cancers. We hope that such a diagnostic indexwill be implemented to help detect breast cancer in the earlystages, thus improving the curability of breast cancer in thefuture.	26749252	2015	Novel Combination of Serum microRNA for Detecting Breast Cancer in the Early Stage	0	1	0	208
chr7	100868036	100868107	MI0022722	hsa-miR-6875	qRT-PCR,etc.	up	In conclusion, our results indicate that a diagnostic indexprepared using a combination of miR-1246, miR-1307-3p, miR-4634, miR-6861-5p and miR-6875-5p measured from serum canbe used to detect breast cancer in the early stages and to differ-entiate breast cancer from pancreas?biliary tract?prostate benigndiseases or other cancers. We hope that such a diagnostic indexwill be implemented to help detect breast cancer in the earlystages, thus improving the curability of breast cancer in thefuture.	26749252	2015	Novel Combination of Serum microRNA for Detecting Breast Cancer in the Early Stage	0	1	0	209
chr11	79402022	79402109	MI0005543	hsa-miR-708	qRT-PCR,etc.	up	Differentially expressed miRNAs from PBMCs may be potential non-invasive biomarkers for breast cancer prediction. Larger prospective studies are required to confirm whether our findings with specific miRNA loci were related to timing before diagnosis.	26124344	2015	microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR	0	1	1	210
chr9	83969748	83969857	MI0000263	hsa-miR-7-1	Luciferase assays,qRT-PCR,Western blot,ChIP,etc.	differential expression	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.	22705304	2012	miR-7 and miR-218 Epigenetically Control Tumor Suppressor Genes RASSF1A and Claudin-6 by Targeting HoxB3 in Breast Cancer	0	0	0	211
chrX	154019920	154019989	MI0012489	hsa-miR-718	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	212
chr15	88611825	88611934	MI0000264	hsa-miR-7-2	Luciferase assays,qRT-PCR,Western blot,ChIP,etc.	differential expression	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.	22705304	2012	miR-7 and miR-218 Epigenetically Control Tumor Suppressor Genes RASSF1A and Claudin-6 by Targeting HoxB3 in Breast Cancer	0	0	0	213
NA	NA	NA	NA	hsa-miR-720	qRT-PCR,microarray,etc.	differential expression	These results point to using high levels of tRNA-derived small RNA fragments in combination with known miR signatures of tumors to distinguish tumor-derived EVs in circulation from EVs derived from other cell sources. Such biomarkers would be unique to the EVs where high abundances of tRNA fragments are amplified with respect to their cellular levels.	25722304	2015	Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments	0	1	0	214
chr19	4770670	4770779	MI0000265	hsa-miR-7-3	Luciferase assays,qRT-PCR,Western blot,ChIP,etc.	differential expression	miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer.	22705304	2012	miR-7 and miR-218 Epigenetically Control Tumor Suppressor Genes RASSF1A and Claudin-6 by Targeting HoxB3 in Breast Cancer	0	0	0	215
chr1	93846832	93846911	MI0005567	hsa-miR-760	microarray,qRT-PCR, ChIP-Seq,etc.	differential expression	MicroRNAs are also integral components of this gene regulation network because miR-107, miR-424, miR-570, miR-618, and miR-760 are regulated by 17beta-estradiol along with other microRNAs that can target a significant number of transcripts belonging to one or more estrogen-responsive gene clusters.	20348243	2010	Estrogen Receptor Alpha Controls a Gene Network in Luminal-Like Breast Cancer Cells Comprising Multiple Transcription Factors and microRNAs	1	0	0	216
chr1	156936131	156936244	MI0005116	hsa-miR-765	qRT-PCR,etc.	differential expression	we identified 10 dysregulated miRNAs in both breast cancer cells and chemoresistant tissues, which might be biomarkers for the prognosis of breast cancer chemoresistance. Our study contributes to a comprehensive understanding of prognostic biomarkers during clinical treatment, and we hypothesize that the miRNA signatures of drug-resistant carcinoma tissues could be useful for developing new strategies for targeted therapies in patients with chemoresistant breast cancer.	25451164	2014	miRNA Expression Patterns in Chemoresistant Breast Cancer Tissues	0	1	1	217
NA	NA	NA	NA	hsa-miR-801	etc.	differential expression	In conclusion, this is the first study to associate circulating miR-127-3p, miR-376a and miR-652 with breast cancer. In addition,we have independently confirmed that miR-127-3p, miR-148b,miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801 levelsare elevated in the plasma of breast cancer patients. ThesemiRNAs can differentiate even women with benign tumors, stage Ior stage II breast cancer from healthy controls thereby reinforcingtheir utility as minimally invasive, early detection markers. Thesubstantial accuracy of breast tumor detection makes thiscirculating miRNA panel a potentially useful (pre)screening tool,especially in younger women for whom mammography seems tobe less sensitive. But, further studies are necessary before thesefindings can be translated into clinical use.	24194846	2013	Plasma MicroRNA Panel for Minimally Invasive Detectionof Breast Cancer	0	1	1	218
chr5	137647572	137647649	MI0005532	hsa-miR-874	qRT-PCR,etc.	up	The miRNA is down-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	219
chrX	145996669	145996743	MI0005528	hsa-miR-892a	microarray,qRT-PCR,etc.	differential expression	Comparative microRNA profiling of sporadic and BRCA4 associated basal-like breast cancers	26152113	2015	Comparative microRNA Profiling of Sporadic and BRCA1 Associated Basal-Like Breast Cancers	0	0	0	220
chr1	156420341	156420429	MI0000466	hsa-miR-9-1	microarray,qRT-PCR,etc.	up	miR-9: increased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	221
NA	NA	NA	NA	hsa-miR-92	qRT-PCR,etc.	differential expression	In summary, the data suggested that miRNAs in milk from milk stasis patients may contribute to breast carcinogenesis and that they are more sensitive biomarkers for breast cancer than miRNAs in the blood.	24584717	2014	miRNA Profiling Reveals a Potential Role of Milk Stasis in Breast Carcinogenesis	0	0	0	222
chr5	88666853	88666939	MI0000467	hsa-miR-9-2	microarray,qRT-PCR,etc.	up	miR-9: increased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	223
chr3	197674496	197674576	MI0005714	hsa-miR-922	qRT-PCR,etc.	up	The miRNA is up-regulated in whole blood of breast cancer patients	22242178	2012	Circulating micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection	0	1	1	224
chr13	91351314	91351391	MI0000093	hsa-miR-92a-1	qRT-PCR,etc.	down	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer	23052693	2013	Circulating microRNA-92a and microRNA-21 as Novel Minimally Invasive Biomarkers for Primary Breast Cancer	0	1	1	225
chrX	134169538	134169612	MI0000094	hsa-miR-92a-2	qRT-PCR,etc.	down	Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer	23052693	2013	Circulating microRNA-92a and microRNA-21 as Novel Minimally Invasive Biomarkers for Primary Breast Cancer	0	1	1	226
chr7	100093768	100093847	MI0000095	hsa-miR-93	microarray,qRT-PCR,etc.	down	This study provides insight into the underlying molecular portrait of Luminal A-like breast cancer subtype. From an initial 76 miRNAs, 4 were validated with altered expression in the blood of women with Luminal A-like breast cancer. The expression profiles of these 3 miRNAs, in combination with mammography, has potential to facilitate accurate subtype-specific breast tumor detection.	24498016	2014	Identification and Validation of Oncologic miRNA Biomarkers for Luminal A-like Breast Cancer	0	1	0	227
chr15	89368017	89368106	MI0000468	hsa-miR-9-3	microarray,qRT-PCR,etc.	up	miR-9: increased expression in c-Myc induced mouse mammary tumors	18777135	2009	Expression profile of microRNAs in c-Myc induced mousemammary tumors	0	0	0	228
chr7	129774692	129774769	MI0000098	hsa-miR-96	microarray,qRT-PCR,etc.	down	Circulating miRNAs reflect the presence of breast tumors. The identification of deregulated miRNAs in plasma of patients with breast cancer supports the use of circulating miRNAs as a method for early breast cancer detection.	26056355	2015	Tumor microRNA Expression Profiling Identifies Circulating microRNAs for Early Breast Cancer Detection	0	1	0	229
NA	NA	NA	NA	hsa-miR-125b	Western Blot,qRT-PCR,Luciferase assay,etc.	down	Results: Luciferase reporter assays showed miRNA-125b directly targeted MMP11. miRNA-125b by transfection with its mimic in breast cancer cells significantly suppressed breast cancer cell proliferation and migration. Western blot revealed that overexpression of miRNA-125b substantially reduced MMP11 protein expression. We used the UALCAN database to investigate the expression of MMP11 in human breast cancer and adjacent normal tissues. In addition, we found that miRNA-125b spoiled MMP11 induced breast cancer cell proliferation and migration promotion effect.Conclusions: miRNA-125b mimic inhibited proliferation, migration, and invasion of breast cancer cells through targeting MMP11 protein. 	32291953	2020	MicroRNA-125b as a tumor suppressor by targeting MMP11 in breast cancer.	0	0	1	230
NA	NA	NA	NA	hsa-miR-9	qRT-PCR,etc.	differential expression	Elevated expression of circACAP2in breast cancer tissues leads to malignant phenotype upon cancerous cells. CircACAP2-miR-29a/b-3p-COL5A1 axis leads to breast cancertumorigenesis andcouldhopefullybe a novel method for diagnosis and treatment for breast cancer	31863774	2020	CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis.	0	0	0	231
chr10	98395218	98395307	MI0006349	hsa-miR-1287	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	232
NA	NA	NA	NA	hsa-miR?143?3p	Western blot,etc.	up	In summary, a PSMG3?AS1?miR?143?3p?COL1A1 regula?tory axis in breast cancer was indicated in the present study. PSMG3?AS1 served as an oncogenic lncRNA that facilitated the genesis and development of breast cancer, by functioning as a ceRNA, which regulated the expression of COL1A1, and also through directly sponging miR?143?3p. In the present study, PSMG3?AS1 was indicated to be a new potential thera?peutic target in breast carcinoma treatment. Invivo studies have revealed the important role of lncRNAs and miRNAs in tumors. For example, H19 was revealed to be associated with tumor development, progression, metastasis and drug resistance (41), and silencing of MALAT1 suppressed the proliferation of GSCs and invivo tumor growth by upregulating miR?129 and inhibiting SOX2 (42)	31661146	2020	Novel lncRNA PSMG3?AS1 functions as a miR?143?3p sponge to increase the proliferation and migration of breast cancer cells.	1	0	0	233
chrX	50003503	50003588	MI0000484	hsa-miR-188	qRT-PCR,etc.	up	In general, this study suggests that miR-188 inhibits theactivation of the MAPK signaling pathway by negatively regulatingRap2c in breast cancer. All of these data revealed a novel tumor\suppressing mechanism in breast cancer, indicating that miR\188may serve as a potential therapeutic target in breast cancer patients	31541458	2020	MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c.	0	0	0	234
NA	NA	NA	NA	hsa-miR-29b	qRT-PCR,etc.	differential expression	Results:MicroRNA array analysis showed significant changes in miRNA expression in both CR and FA conditions innormal liver. Expression of miR-29 and miR-30 family members was increased in both CR and FA. Western blot analysisof the normal liver tissue showed that CR and FA downregulated the IGF-1/Akt pathway and qRT-PCR showed that theexpression of miR-29b, miR-29c, miR-30a and miR-30b were increased with CR and FA. Liver tissue collected from micein the breast cancer model showed an increase in expression of miR-29b, miR-29c and miR-30b while tumor tissueshowed increased expression of miR-29c, miR-30a and miR-30b.	32211051	2020	Dietary alterations modulate the microRNA 29/30 and IGF-1/AKT signaling axis in breast Cancer liver metastasis.	0	0	1	235
chr1	207801852	207801939	MI0000735	hsa-miR-29c	qRT-PCR,etc.	differential expression	Results:MicroRNA array analysis showed significant changes in miRNA expression in both CR and FA conditions innormal liver. Expression of miR-29 and miR-30 family members was increased in both CR and FA. Western blot analysisof the normal liver tissue showed that CR and FA downregulated the IGF-1/Akt pathway and qRT-PCR showed that theexpression of miR-29b, miR-29c, miR-30a and miR-30b were increased with CR and FA. Liver tissue collected from micein the breast cancer model showed an increase in expression of miR-29b, miR-29c and miR-30b while tumor tissueshowed increased expression of miR-29c, miR-30a and miR-30b.	32211051	2020	Dietary alterations modulate the microRNA 29/30 and IGF-1/AKT signaling axis in breast Cancer liver metastasis.	0	0	1	236
NA	NA	NA	NA	hsa-miR-302	etc.	down	Results: Ectopic expression of miR-302/367 cluster downregulated expression of some downstream elements of TGF- pathway in MDA-MB-231 and SK-BR-3 breast cancer cell lines. Overexpression of miR-302/367 cluster inhibited proliferation of the breast cancer cells by suppressing the S-phase of cell cycle which was in accordance with inhibition of TGF- pathway. Conclusion: TGF- signaling is one of the key pathways in tumor progression and a general suppression of TGF- mediators by the pleiotropically acting miR-302/367 cluster may be one of the important reasons for its anti-tumor effects in breast cancer cells.	31376326	2020	Repression of TGF- Signaling in Breast Cancer Cells by miR-302/367 Cluster.	0	0	0	237
chr6	71403551	71403621	MI0000088	hsa-miR-30a	qRT-PCR,etc.	differential expression	Results:MicroRNA array analysis showed significant changes in miRNA expression in both CR and FA conditions innormal liver. Expression of miR-29 and miR-30 family members was increased in both CR and FA. Western blot analysisof the normal liver tissue showed that CR and FA downregulated the IGF-1/Akt pathway and qRT-PCR showed that theexpression of miR-29b, miR-29c, miR-30a and miR-30b were increased with CR and FA. Liver tissue collected from micein the breast cancer model showed an increase in expression of miR-29b, miR-29c and miR-30b while tumor tissueshowed increased expression of miR-29c, miR-30a and miR-30b.	32211051	2020	Dietary alterations modulate the microRNA 29/30 and IGF-1/AKT signaling axis in breast Cancer liver metastasis.	0	0	1	238
chr8	134800520	134800607	MI0000441	hsa-miR-30b	qRT-PCR,etc.	differential expression	Results:MicroRNA array analysis showed significant changes in miRNA expression in both CR and FA conditions innormal liver. Expression of miR-29 and miR-30 family members was increased in both CR and FA. Western blot analysisof the normal liver tissue showed that CR and FA downregulated the IGF-1/Akt pathway and qRT-PCR showed that theexpression of miR-29b, miR-29c, miR-30a and miR-30b were increased with CR and FA. Liver tissue collected from micein the breast cancer model showed an increase in expression of miR-29b, miR-29c and miR-30b while tumor tissueshowed increased expression of miR-29c, miR-30a and miR-30b.	32211051	2020	Dietary alterations modulate the microRNA 29/30 and IGF-1/AKT signaling axis in breast Cancer liver metastasis.	0	0	1	239
chr4	112647874	112647941	MI0000775	hsa-miR-367	etc.	down	Results: Ectopic expression of miR-302/367 cluster downregulated expression of some downstream elements of TGF- pathway in MDA-MB-231 and SK-BR-3 breast cancer cell lines. Overexpression of miR-302/367 cluster inhibited proliferation of the breast cancer cells by suppressing the S-phase of cell cycle which was in accordance with inhibition of TGF- pathway. Conclusion: TGF- signaling is one of the key pathways in tumor progression and a general suppression of TGF- mediators by the pleiotropically acting miR-302/367 cluster may be one of the important reasons for its anti-tumor effects in breast cancer cells.	31376326	2020	Repression of TGF- Signaling in Breast Cancer Cells by miR-302/367 Cluster.	0	0	0	240
NA	NA	NA	NA	hsa-miR-3676-5p	microarray,qRT-PCR,etc.	up	Overexpressed in BRCA1/2-associated BCs	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	241
NA	NA	NA	NA	hsa-miR-4433	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	242
chr11	46376402	46376484	MI0017321	hsa-miR-4688	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	243
chr2	66358297	66358318	MIMAT0019936	hsa-miR-4778-5p	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	244
chr14	101052446	101052525	MI0002471	hsa-miR-487a	qRT-PCR,ChIP,Western blot,Luciferase assay,etc.		In conclusion, this study unveiled the critical role ofcircRNF20 in the BC progress and Warburg effect.Mechanistically, circRNF20 harbor miR-487a, acting asmiRNA sponge, and then miR-487a targeted the 3-UTRof hypoxia-inducible factor-1(HIF-1). Moreover, HIF-1could bind with the promoter of HK2 and promoted itstranscription. Thefinding illustrates the vital role ofcircRNF20/ miR-487a/HIF-1/HK2 axis in BCtumorigenesis.	32094325	2020	Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect through miR-487a/HIF-1/HK2.	0	0	1	245
chr17	42514208	42514229	MIMAT0021043	hsa-miR-5010-5p	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	246
NA	NA	NA	NA	hsa-miR-663	qRT-PCR,etc.	up	The exhilarating and fast-growing field of miRNAs and their ver-satilityintargetedtherapyagainstcancer,mayonedaybepracticable.Abnormal expression of miRNAs has been observed in most of thecancertype'srightthroughcancerearlierandlatestages.Thus,miRNAsportray as a very strong target in cancer therapy. Phytological-com-pound mediated therapy displayed a unique ability to modify miRNAslevel implicated in controlling pathobiology of cancer via transcrip-tional, miRNA processing and epigenetic mechanisms. These naturalcompoundsevaluatedbothin-vivoandinclinicaltrialsmightbeusedtotargetdiversesignalingpathwaysthroughspecificmiRNAs.Inaddition,phytological-compounds found to increase the chemo-sensitivity oftraditionaldrugsthroughmodulatingmiRNAs.Thesecompoundsmightbe subjugated for scheming therapeutic approaches in combinationwith traditional remedies to improve cancer therapies and prevention.Thereisanextensivescopeforthedevelopmentofphytochemicalintocommercial drugs to efficaciously prevent and treat cancer	31982837	2020	Modification of miRNA Expression through plant extracts and compounds against breast cancer: Mechanism and translational significance.	0	0	0	247
chr2	132256966	132257080	MI0006336	hsa-miR-663b	microarray,qRT-PCR,etc.	down	In conclusion, this study revealed multiple deregulated miRNAs in BRCA1/2-associated breast carcinomas, some shared with sporadic breast carcinomas, but several possibly specific to BRCA1/2 carcinogenesis. Specific deregulated miRNAs in BRCA1/2-associated carcinomas appear to target similar pathways. This suggests the existence of common targetable miRNA regulated pathways driving BRCA1/2-associated breast carcinogenesis. These findings warrant further studies on the role of these miRNAs in BRCA1/2-associated breast carcinogenesis. 	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	248
chr8	143813010	143813029	MIMAT0022938	hsa-miR-937-5p	microarray,qRT-PCR,etc.	up	Overexpressed in BRCA1/2-associated BCs	26378051	2015	miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers 	0	0	0	249
NA	NA	NA	NA	hsa-miR-5119	qRT-PCR,luciferase assays,etc.	differential expression	In summary, this study, for the first time, develops a novel immunotherapy using miR-5119 mimic-engineered DCs for treatment of breast cancer. Engineering DCs with miR-5119 simultaneously repressed multiple negative regulatory mole-cules, including IR ligands such as PD-L1 and IDO2 in DCs which, in turn, stimulate anti-tumor immune response and upregulate cytokine production while simultaneously reduc-ing IR expression in, and apoptosis of, T cells. Furthermore, treatment with miR-5119 mimic-engineered DC vaccine dis-played pre-clinical efficacy in controlling mouse syngeneic homograft tumor growth, in association with reduced T cell apoptosis and enhanced anti-breast cancer tumor immunity. This study reveals a new strategy for miRNA/DC-based immunotherapy and highlights potential to enhance therapy for breast and other cancers.	32076794	2020	miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.	0	0	0	250
chr7	129774739	129774761	MIMAT0000095	hsa-miR-96-5p	qRT-PCR,Western blot,Luciferase assay,etc.	differential expression	Results: Luciferase reporter assays showed miRNA-96-5p directly targeted FOXO3. Abrogation of miRNA-96-5p by transfection with its inhibitors in breast cancer cells significantly suppressed miRNA-96-5p expression and breast cancer cells proliferation. Western blot revealed that overexpression of miRNA-96-5p substantially reduced FOXO3 protein expression. We used the GEPIA, UALCAN and KM-plotter databases to investigate the expression of FOXO3 in human breast cancer and adjacent normal tissues, and its correlation with survival. In addition, we found that FOXO3 spoiled miR-96-5p induced breast cancer cell proliferation block effecting.Conclusions: miRNA-96-5p may exert a tumor promotion role through negatively regulating tumor suppressor gene FOXO3 and promoting cell proliferation. 	32100957	2020	MiRNA-96-5p impacts the progression of breast cancer through targeting FOXO3.	0	0	1	251
NA	NA	NA	NA	hsa-miR-106 	qRT-PCR,RNA-seq,etc.	up	In our study, there was still some weakness that deservesto be acknowledged. First, the molecular mechanisms by whichmiR-106b and EMT-related molecules in CTCs regulate tumorprogression were not presented in this study. However, several reasons are responsible for this limitation. As far as we know,the isolation and enrichment as well as ex vivo culture of viableCTCs are still technically challenging, and the frequency of CTCin the peripheral blood of patients with solid tumors variesamong individual patients with different prior systemic thera-pies. In recent years, although a few papers reported that thegenome alternation of CTC lines and suspended cancer cellsmay be related to the drug sensitivity in both in vitro and xeno-grafts models in breast cancer [53], the evidence is indirect andnot strong enough because of the above limitations. Second,the downstream targeted molecules of miR-106b related toEMT should be further tested in our future studies.	31300482	2019	Incorporating MicroRNA Into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients With Metastatic Breast Cancer	1	1	1	252
chr19	13836440	13836517	MI0000085	hsa-miR-27a	qRT-PCR,etc.	up	Results:Both expression and mean rank of miR 27a and tumor markers among BC patients as com-pared to the other two groups. Clinicopathological characteristics showed significant relation withmiRN 27a expression for clinical stage, histological grading, ER receptor and HER-2/neu. The diagnosticefficacy for miR 27a was superior to both tumor markers for early detection of BC especially high-riskBC groups.Conclusion:Detection of miR 27a expression may serve as a potential sensitive minimally invasivemolecular marker for early detection of primary BC.	31145011	2019	Serum MiRNA-27a as Potential Diagnostic Nucleic Marker for Breast Cancer	0	1	0	253
chr12	95308420	95308513	MI0000812	hsa-miR-331	qRT-PCR,etc.	up	Results:Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressedin patients with metastatic disease, compared to patients with local disease (p< 0.001) or healthy controls(p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patientswith local disease (p < 0.001) or healthy controls (p= 0.043). In combination, miR-331 and miR-195 produced anAUC of 0.902, distinguishing metastatic from local breast cancer.Conclusions:We identified and validated two circulating miRNAs differentiating local Luminal A breast cancersfrom metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis,and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identifymetastatic disease, and potentially inform diagnosis or treatment effectiveness.	31077182	2019	Circulating microRNAs miR-331 and miR-195 differentiate local luminal a frommetastatic breast cancer	0	1	0	254
chr17	7017615	7017701	MI0000489	hsa-miR-195	qRT-PCR,etc.	down	Results:Of 4 miRNA targets tested (miR-181a, miR-329, miR-331, miR-195), mir-331 was significantly over-expressedin patients with metastatic disease, compared to patients with local disease (p< 0.001) or healthy controls(p < 0.001). miR-195 was significantly under-expressed in patients with metastatic disease, compared to patientswith local disease (p < 0.001) or healthy controls (p= 0.043). In combination, miR-331 and miR-195 produced anAUC of 0.902, distinguishing metastatic from local breast cancer.Conclusions:We identified and validated two circulating miRNAs differentiating local Luminal A breast cancersfrom metastatic breast cancers. Further investigation will reveal the molecular role of these miRNAs in metastasis,and determine if they are subtype specific. This work demonstrates the ability of circulating miRNA to identifymetastatic disease, and potentially inform diagnosis or treatment effectiveness.	31077182	2019	Circulating microRNAs miR-331 and miR-195 differentiate local luminal a frommetastatic breast cancer	0	1	1	255
chr17	59841266	59841337	MI0000077	hsa-miR-21 	qRT-PCR,etc.	up	Upregulation of miR-21 expression at diagnosis was determined as an average miR-21 expression in healthy women plus 2xSD as described at the Material and Methods. Progression-free survival was compared between patients with and without miR-21 upregulation at diagnosis. Patients with miR-21 upregulation showed shorter progression-free survival, median survivals were 72 vs 86 weeks and Mantel-Cox test p=0.049, Fig	31030498	2019	Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer	0	1	1	256
chr18	58451074	58451158	MI0000442	hsa-miR-122	qRT-PCR,etc.	up	Based on our results, we suggest the utilization of micro-RNA 122 as a biomarker during screening, diagnosis and prognosis assessments in breast cancer patients. Specifically, we propose the measurement of circulating microRNA 122 levels as a practical method to predict metastasis in breast cancer patients, which can affect the selection of treatment protocols and appeared to perform much better than the commonly used tumor markers CEA and CA15-3.	30835039	2019	Potential Value of Circulatory microRNA122 Gene Expression as a Prognostic and Metastatic Prediction Marker for Breast Cancer	0	1	1	257
chr17	59841266	59841337	MI0000077	hsa-miR-21 	qRT-PCR,etc	up	In conclusion, the increased expression and the interre-lation of both breast tissue and exosomal miR-21 in DCIS,and IDC and their inverse correlation with theforemostnuclear expression of PDCD protein signifies the onco-genic role of miR-21 in pathogenesis and the spread ofbreast cancer in these patients, as well as its potential use asa biomarker for disease screening and response to therapy.	30728670	2019	Interrelation of the Circulating and Tissue MicroRNA-21 With Tissue PDCD4 Expression and the Invasiveness of Iraqi Female Breast Tumors	0	1	1	258
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,etc	up	Results:Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastaticversus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like(p= 0.037) and in luminal B versus luminal A (p= 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlatedwith clinical and pathological variables such as progesterone receptor status (p= 0.017) and Ki67 (p= 0.05). Duringneoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p= 0.039) andinversely with Ki67 expression (p= 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155were significantly associated with the presence of circulating tumor cells.Conclusion:Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementaryclinical tool for improving breast cancer diagnosis and prognosis	30728048	2019	Exosomal miRNA profile as complementarytool in the diagnostic and prediction oftreatment response in localized breastcancer under neoadjuvant chemotherapy	0	1	0	259
NA	NA	NA	NA	hsa-miR-105 	qRT-PCR,etc	up	Results:Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastaticversus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like(p= 0.037) and in luminal B versus luminal A (p= 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlatedwith clinical and pathological variables such as progesterone receptor status (p= 0.017) and Ki67 (p= 0.05). Duringneoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p= 0.039) andinversely with Ki67 expression (p= 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155were significantly associated with the presence of circulating tumor cells.Conclusion:Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementaryclinical tool for improving breast cancer diagnosis and prognosis	30728048	2019	Exosomal miRNA profile as complementarytool in the diagnostic and prediction oftreatment response in localized breastcancer under neoadjuvant chemotherapy	0	1	0	260
chrX	45747015	45747124	MI0000299	hsa-miR-222 	qRT-PCR,etc	up	Results:Before neoadjuvant therapy, exosomal miRNA-21 and 105 expression levels were higher in metastaticversus non-metastatic patients and healthy donors. Likewise, higher levels of miRNA-222 were observed in basal-like(p= 0.037) and in luminal B versus luminal A (p= 0.0145) tumor subtypes. Exosomal miRNA-222 levels correlatedwith clinical and pathological variables such as progesterone receptor status (p= 0.017) and Ki67 (p= 0.05). Duringneoadjuvant treatment, exosomal miRNA-21 expression levels directly correlated with tumor size (p= 0.039) andinversely with Ki67 expression (p= 0.031). Finally, higher levels of exosomal miRNA-21, miRNA-222, and miRNA-155were significantly associated with the presence of circulating tumor cells.Conclusion:Liquid biopsies based on exosomal miRNAs and circulating tumor cells can be a complementaryclinical tool for improving breast cancer diagnosis and prognosis	30728048	2019	Exosomal miRNA profile as complementarytool in the diagnostic and prediction oftreatment response in localized breastcancer under neoadjuvant chemotherapy	0	1	0	261
chr11	122099809	122099830	MIMAT0000423	hsa-miR-125b-5p	qRT-PCR,etc	up	Our study highlighted that the addition of PET/MR biomarkers led to a better understanding ofthe relationships between circulating miRNAs and tumour biology in our BC population. Nevertheless,further studies with larger samples and a more homogeneous distribution of tumour subtypes andstaging are needed to confirm our results	31234535	2019	Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study	0	1	1	262
chr5	149428978	149428998	MIMAT0000435	hsa-miR-143-3p	qRT-PCR,etc	up	Our study highlighted that the addition of PET/MR biomarkers led to a better understanding ofthe relationships between circulating miRNAs and tumour biology in our BC population. Nevertheless,further studies with larger samples and a more homogeneous distribution of tumour subtypes andstaging are needed to confirm our results	31234535	2019	Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study	0	1	1	263
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	264
NA	NA	NA	NA	hsa-miR-23	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	265
chr1	1167104	1167198	MI0000342	hsa-miR-200b	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	266
chr12	6963699	6963766	MI0000650	hsa-miR-200c	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	267
chr9	95085208	95085304	MI0000439	hsa-miR-23b	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	268
NA	NA	NA	NA	hsa-miR-190 	qRT-PCR,etc	up	Based on the above findings we sought to evaluate whether the aforementioned miRNAs could also discriminate among patients with early and MBC and whether they could be used for the refinement of prognosis in patients with metastatic disease.	30847025	2019	Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.	0	1	1	269
chr5	149430646	149430733	MI0000461	hsa-miR-145	qRT-PCR,etc	up	We found that miR-16 is upregulated in patients comparedto the control group by the absolute quantification method.Consequently, miR-16 is not a suitable normaliser for the rel-ative expression profiling of miRNAs in luminal A breastcancer patients. in addition to miR-16, another five miRNAs(miR-145, miR-155, miR-451a, miR-21 and miR-486) werefound to be upregulated and one miRNA (miR-195) wasfound to be downregulated when analysed using absolutequantification. The combination of miR-145, miR-195 andmiR-486 resulted in the best diagnostic value (AUC = 0.875,sensitivity = 76% and specificity = 81%) for luminal A breastcancer	30840191	2019	Relative and Absolute Expression Analysis of MicroRNAs Associated With Luminal A Breast Cancer- A Comparison	0	1	0	270
chr17	7017615	7017701	MI0000489	hsa-miR-195	qRT-PCR,etc	up	We found that miR-16 is upregulated in patients comparedto the control group by the absolute quantification method.Consequently, miR-16 is not a suitable normaliser for the rel-ative expression profiling of miRNAs in luminal A breastcancer patients. in addition to miR-16, another five miRNAs(miR-145, miR-155, miR-451a, miR-21 and miR-486) werefound to be upregulated and one miRNA (miR-195) wasfound to be downregulated when analysed using absolutequantification. The combination of miR-145, miR-195 andmiR-486 resulted in the best diagnostic value (AUC = 0.875,sensitivity = 76% and specificity = 81%) for luminal A breastcancer	30840191	2019	Relative and Absolute Expression Analysis of MicroRNAs Associated With Luminal A Breast Cancer- A Comparison	0	1	0	271
NA	NA	NA	NA	hsa-miR-486 	qRT-PCR,etc	up	We found that miR-16 is upregulated in patients comparedto the control group by the absolute quantification method.Consequently, miR-16 is not a suitable normaliser for the rel-ative expression profiling of miRNAs in luminal A breastcancer patients. in addition to miR-16, another five miRNAs(miR-145, miR-155, miR-451a, miR-21 and miR-486) werefound to be upregulated and one miRNA (miR-195) wasfound to be downregulated when analysed using absolutequantification. The combination of miR-145, miR-195 andmiR-486 resulted in the best diagnostic value (AUC = 0.875,sensitivity = 76% and specificity = 81%) for luminal A breastcancer	30840191	2019	Relative and Absolute Expression Analysis of MicroRNAs Associated With Luminal A Breast Cancer- A Comparison	0	1	0	272
chr16	69933103	69933124	MIMAT0000431	hsa-miR-140-5p 	qRT-PCR,etc	up	Conclusions: ct-miRNAs discriminate patients with and without pCR after neoadjuvant lapatinib- and/or trastuzumab-based therapy. ct-miRNAs at week two could be valuable to identify patients responsive to trastuzumab, to avoid unnecessary combination with other anti-HER2 agents, and finally to assist deescalating treatment strategies. 	30814109	2019	Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: results from the NeoALTTO trial. 	0	1	0	273
chr7	130496111	130496204	MI0000816	hsa-miR-335	qRT-PCR,etc.	down	Results: A significant decrease in miRNA-335 expression was reported in patients with breast cancer as compared to the other two investigated groups. The positivity rate for miRNA were related to adverse clinical features of primary breast cancer as high histological grading (X2 = 7.72, P = 0.016), presence of metastasis to lymph node (X2 = 21.8, P < 0.001), large tumor size (X2 = 6.41, P = 0.041), and hormonal status (P < 0.001). miRNA-335 mean rank level was significantly different among breast cancer subtypes and its level was inferior in triple negative breast cancer. Worse DFS (X2 = 7.76, P = 0.005) and OS (X2 = 9.3, P = 0.002) were reported with decreased miRNA-335 level.Conclusion: Assessment of circulating miRNA expression level is a promising minimal invasive marker for diagnosis and prediction of breast cancer prognosis with significant discrepancies among molecular breast cancer subtypes. 	30506730	2019	Clinical Aspects of Circulating miRNA-335 in Breast Cancer Patients: A Prospective Study	0	1	0	274
chr21	16539101	16539122	MIMAT0000097	hsa-miR-99a-5p	qRT-PCR,etc.	down	Results: The miRNA candidates in our method were revealed to be associated with breast cancer according to previous studies and showed potential as useful biomarkers. When validated in independent serum samples, the area under curve of the final miRNA signature (miR-21-3p, miR-21-5p, and miR-99a-5p) was 0.895. Diagnostic sensitivity and specificity were 97.9% and 73.5%, respectively.Conclusion: The present study established a novel and effective method to identify biomarkers for early breast cancer. And the method, is also suitable for other cancer types. Furthermore, a combination of three miRNAs was identified as a prospective biomarker for breast cancer early detection. 	30607157	2018	Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data	0	1	0	275
NA	NA	NA	NA	hsa-miR-21-3p/-5p	qRT-PCR,etc.	up	Results: The miRNA candidates in our method were revealed to be associated with breast cancer according to previous studies and showed potential as useful biomarkers. When validated in independent serum samples, the area under curve of the final miRNA signature (miR-21-3p, miR-21-5p, and miR-99a-5p) was 0.895. Diagnostic sensitivity and specificity were 97.9% and 73.5%, respectively.Conclusion: The present study established a novel and effective method to identify biomarkers for early breast cancer. And the method, is also suitable for other cancer types. Furthermore, a combination of three miRNAs was identified as a prospective biomarker for breast cancer early detection. 	30607157	2018	Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data	0	1	0	276
chr13	91350605	91350688	MI0000071	hsa-miR-17 	qRT-PCR,etc.	up	In summary, our study indicated the upregulation ofmiR\17, and downregulation of miR\25 and miR\133 inpatients serum.Examination based on serum miRNA profiling wasfollowed by qRT\PCR validation, so we identified threemiRNAs (miR\17, miR\25, and miR\133) that areinvolved in patients with breast cancer relative to healthycontrols. Detection of the expression levels of each of thethree miRNAs could significantly distinguish breastcancer and healthy controls. Moreover, these miRNAswere associated with the several important cancer\relatedpathways and breast cancer survival. These resultssuggest that the identified miRNAs may play importantroles in the breast cancer development and progression,and may serve as potential biomarkers for the earlydetection of breast cancer	30485486	2018	Expression of Circulating miR-17, miR-25, and miR-133 in Breast Cancer Patients	0	1	0	277
NA	NA	NA	NA	hsa-miR-133	qRT-PCR,etc	down	In summary, our study indicated the upregulation ofmiR\17, and downregulation of miR\25 and miR\133 inpatients serum.Examination based on serum miRNA profiling wasfollowed by qRT\PCR validation, so we identified threemiRNAs (miR\17, miR\25, and miR\133) that areinvolved in patients with breast cancer relative to healthycontrols. Detection of the expression levels of each of thethree miRNAs could significantly distinguish breastcancer and healthy controls. Moreover, these miRNAswere associated with the several important cancer\relatedpathways and breast cancer survival. These resultssuggest that the identified miRNAs may play importantroles in the breast cancer development and progression,and may serve as potential biomarkers for the earlydetection of breast cancer	30485486	2018	Expression of Circulating miR-17, miR-25, and miR-133 in Breast Cancer Patients	0	1	0	278
chr7	100093560	100093643	MI0000082	hsa-miR-25 	qRT-PCR,etc	down	In summary, our study indicated the upregulation ofmiR\17, and downregulation of miR\25 and miR\133 inpatients serum.Examination based on serum miRNA profiling wasfollowed by qRT\PCR validation, so we identified threemiRNAs (miR\17, miR\25, and miR\133) that areinvolved in patients with breast cancer relative to healthycontrols. Detection of the expression levels of each of thethree miRNAs could significantly distinguish breastcancer and healthy controls. Moreover, these miRNAswere associated with the several important cancer\relatedpathways and breast cancer survival. These resultssuggest that the identified miRNAs may play importantroles in the breast cancer development and progression,and may serve as potential biomarkers for the earlydetection of breast cancer	30485486	2018	Expression of Circulating miR-17, miR-25, and miR-133 in Breast Cancer Patients	0	1	0	279
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,etc	up	In summary, we successfully developed a single-molecule method for the quantification of circulating miRNA biomarkers. Taking the advantage of the sensitivity of TIRFM-based single-molecule platform and the amplification of CHA, rapid and sensitive miRNA detection with low background signal was readily achieved. With smCHA, synthetic miRNA targets can be detected in solution with an excellent detection limit below 0.02 fM, and the circulating miRNAs can be quantified showing a good agreement with the RT-qPCR as gold standard. Differential levels of circulating miRNAs were discovered between cancer samples and healthy controls. Our method avoids the steps of RNA isolation, PCR amplification, and elaborated result analysis which typically take roughly 3-4 h. smCHA can deliver result of single sample within 0.5 h (10 min for pretreatment, 15 min for CHA, and 5 min for single-molecule counting). Multiplexing can achieved by using different fluorophores or other fingerprinting labels. smCHA would find more applications in biomarker detection and DNA-based biosensing. 	30428976	2018	Single-molecule Catalytic Hairpin Assembly for Rapid and Direct Quantification of Circulating miRNA Biomarkers	0	1	0	280
chr12	6964097	6964191	MI0000457	hsa-miR-141	qRT-PCR,etc	up	In summary, we successfully developed a single-molecule method for the quantification of circulating miRNA biomarkers. Taking the advantage of the sensitivity of TIRFM-based single-molecule platform and the amplification of CHA, rapid and sensitive miRNA detection with low background signal was readily achieved. With smCHA, synthetic miRNA targets can be detected in solution with an excellent detection limit below 0.02 fM, and the circulating miRNAs can be quantified showing a good agreement with the RT-qPCR as gold standard. Differential levels of circulating miRNAs were discovered between cancer samples and healthy controls. Our method avoids the steps of RNA isolation, PCR amplification, and elaborated result analysis which typically take roughly 3-4 h. smCHA can deliver result of single sample within 0.5 h (10 min for pretreatment, 15 min for CHA, and 5 min for single-molecule counting). Multiplexing can achieved by using different fluorophores or other fingerprinting labels. smCHA would find more applications in biomarker detection and DNA-based biosensing. 	30428976	2018	Single-molecule Catalytic Hairpin Assembly for Rapid and Direct Quantification of Circulating miRNA Biomarkers	0	1	0	281
chr12	6963699	6963766	MI0000650	hsa-miR-200c	qRT-PCR,etc.	up	Results: The mean level of miRNA-200c was significantly higher in the ER(+)/PR(+) group than in the TNBC group (p < 0.05). No statistically significant difference was found between the two groups with regard to the mean levels of miRNA-21 or miRNA-10b.Conclusion: The level of miRNA-200c was lower in triple-negative patients when compared with the levels in the study's ER/PR positive group. 	30215459	2018	Serum Levels of Circulating miRNA-21, miRNA-10b and miRNA-200c in Triple-Negative Breast Cancer Patients	0	1	0	282
chr7	129770383	129770492	MI0000272	hsa-miR-182	qRT-PCR,etc.	up	Results: miRNA 182 expression was significantly higher in group II, group IV, and group V (3.36  0.14, 2.52  0.34, and 4.93  0.3,9 respectively); miRNA 375 expression was significantly higher in group II, group IV, and group V (4.41  0.40, 3.12  0.35, and 11.28  2.37, respectively) (P < .05). Both miRNAs were significantly associated with each other and with receptors used for the prognosis of BC even after multiple regression analysis.Conclusion: Accordingly, miRNAs 182 and 375 could be potential noninvasive markers used for the follow up of BC patients. 	30143449	2018	MicroRNAs 182 and 375 Sera Expression as Prognostic Biochemical Markers in Breast Cancer	0	1	0	283
chr2	219001645	219001708	MI0000783	hsa-miR-375	qRT-PCR,etc.	up	Results: miRNA 182 expression was significantly higher in group II, group IV, and group V (3.36  0.14, 2.52  0.34, and 4.93  0.3,9 respectively); miRNA 375 expression was significantly higher in group II, group IV, and group V (4.41  0.40, 3.12  0.35, and 11.28  2.37, respectively) (P < .05). Both miRNAs were significantly associated with each other and with receptors used for the prognosis of BC even after multiple regression analysis.Conclusion: Accordingly, miRNAs 182 and 375 could be potential noninvasive markers used for the follow up of BC patients. 	30143449	2018	MicroRNAs 182 and 375 Sera Expression as Prognostic Biochemical Markers in Breast Cancer	0	1	0	284
chrX	45747036	45747056	MIMAT0000279	hsa-miR-222-3p	Microarray	up	In these premises, we postulated that specific miRNAssecreted into circulation by the tumor would decreaseafter tumor resection, which might serve as a potentialbiomarker to track the tumor. Thus, our study was carriedout by longitudinal comparison of miRNA profiles beforeand after surgery in individual patients. We aimed toinvestigate the diagnostic and prognostic value of thedownregulated miRNAs after surgery in breast cancer.	30109140	2018	Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discov. 	0	1	1	285
chrX	45747015	45747124	MI0000299	hsa-miR-222	qRT-PCR,microarray,etc.	up	Results: Based on the results of microRNA profiling, seven miRNAs were selected for further validation. In the HR+/HER2- cohort (n = 51) dynamics of three miRNAs, including miR-222, miR-20a, and miR-451, were associated with chemo-sensitivity. Importantly, across all the three subtypes we consistently identified chemo-induced decrease in plasma miR-34a in the insensitive patients. Finally, baseline miR-222 overexpression (OR = 6.422, P = 0.049), C2 miR-20a up-regulation (OR = 0.144, P = 0.021) and C2 miR-451 down-regulation (OR = 8.213, P = 0.012) were predictive markers of response to NCT in HR+/HER2- breast cancer.Conclusions: We described that dynamics of circulating miRNAs might help predict clinical response to NCT in breast cancer. 	30099860	2018	Dynamics of Circulating microRNAs as a Novel Indicator of Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer	0	1	0	286
chr13	91351065	91351135	MI0000076	hsa-miR-20a	qRT-PCR,microarray,etc.	up	Results: Based on the results of microRNA profiling, seven miRNAs were selected for further validation. In the HR+/HER2- cohort (n = 51) dynamics of three miRNAs, including miR-222, miR-20a, and miR-451, were associated with chemo-sensitivity. Importantly, across all the three subtypes we consistently identified chemo-induced decrease in plasma miR-34a in the insensitive patients. Finally, baseline miR-222 overexpression (OR = 6.422, P = 0.049), C2 miR-20a up-regulation (OR = 0.144, P = 0.021) and C2 miR-451 down-regulation (OR = 8.213, P = 0.012) were predictive markers of response to NCT in HR+/HER2- breast cancer.Conclusions: We described that dynamics of circulating miRNAs might help predict clinical response to NCT in breast cancer. 	30099860	2018	Dynamics of Circulating microRNAs as a Novel Indicator of Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer	0	1	0	287
NA	NA	NA	NA	hsa-miR-451	qRT-PCR,microarray,etc.	down	Results: Based on the results of microRNA profiling, seven miRNAs were selected for further validation. In the HR+/HER2- cohort (n = 51) dynamics of three miRNAs, including miR-222, miR-20a, and miR-451, were associated with chemo-sensitivity. Importantly, across all the three subtypes we consistently identified chemo-induced decrease in plasma miR-34a in the insensitive patients. Finally, baseline miR-222 overexpression (OR = 6.422, P = 0.049), C2 miR-20a up-regulation (OR = 0.144, P = 0.021) and C2 miR-451 down-regulation (OR = 8.213, P = 0.012) were predictive markers of response to NCT in HR+/HER2- breast cancer.Conclusions: We described that dynamics of circulating miRNAs might help predict clinical response to NCT in breast cancer. 	30099860	2018	Dynamics of Circulating microRNAs as a Novel Indicator of Clinical Response to Neoadjuvant Chemotherapy in Breast Cancer	0	1	0	288
chr1	177029363	177029445	MI0003123	hsa-miR-488	Microarray,qRT-PCR,etc.	up	Results: A positive correlation was noted between pre-miR-488 and miR-488-5p expression in blood. In 330 cases of surgically-treated breast cancer, high expression of circulating pre-miR-488 was an independent poor prognostic factor for recurrence-free survival.Conclusion: Circulating pre-miR-488 expression could be a novel prognostic biomarker for predicting recurrence in breast cancer patients. 	30061217	2018	Circulating pre-microRNA-488 in peripheral blood is a potential biomarker for predicting recurrence in breast cancer. 	0	1	0	289
chr10	21496576	21496595	MIMAT0007892	hsa-miR-1915-3p	Microarray,etc.	up	Results: A positive correlation was noted between pre-miR-488 and miR-488-5p expression in blood. In 330 cases of surgically-treated breast cancer, high expression of circulating pre-miR-488 was an independent poor prognostic factor for recurrence-free survival.Conclusion: Circulating pre-miR-488 expression could be a novel prognostic biomarker for predicting recurrence in breast cancer patients. 	30061217	2018	Circulating pre-microRNA-488 in peripheral blood is a potential biomarker for predicting recurrence in breast cancer. 	0	1	0	290
chr9	114209487	114209507	MIMAT0004784	hsa-miR-455-3p	Microarray,etc.	down	Results: A positive correlation was noted between pre-miR-488 and miR-488-5p expression in blood. In 330 cases of surgically-treated breast cancer, high expression of circulating pre-miR-488 was an independent poor prognostic factor for recurrence-free survival.Conclusion: Circulating pre-miR-488 expression could be a novel prognostic biomarker for predicting recurrence in breast cancer patients. 	30061217	2018	Circulating pre-microRNA-488 in peripheral blood is a potential biomarker for predicting recurrence in breast cancer. 	0	1	0	291
chr17	59841266	59841337	MI0000077	hsa-miR-21	qRT-PCR,etc.	up	Results: miR-21 (p < 0.001), miR-23b (p = 0.028) and miR-200c (p < 0.001) expression were higher and miR-190 was lower (p = 0.013) in relapsed (n = 49), compared to non-relapsed patients (n = 84). Interestingly, miR-190 was lower (p = 0.0032) in patients with early relapse (at < 3 years; n = 23) compared to those without early relapse (n = 110). On the other hand, miR-21 and miR-200c were higher (p = 0.015 and p < 0.001, respectively) in patients with late relapse (relapse at  5 years; n = 20) as compared to non-relapsed patients. High miR-200c was associated with shorter disease-free survival (DFS) (p = 0.005) and high miR-21 with both shorter DFS and overall survival (OS) (p < 0.001 and p = 0.033, respectively) compared to low expression. ROC curve analysis revealed that miR-21, miR-23b, miR-190 and miR-200c discriminated relapsed from non-relapsed patients. A combination of of miR-21, miR-23b and miR-190 showed higher sensitivity and specificity in ROC analyses compared to each miRNA alone; accuracy was further improved by adding lymph node infiltration and tumor grade to the panel of three miRs (AUC 0.873). Furthermore, the combination of miR-200c, lymph node infiltration, tumor grade and estrogen receptor predicted late relapse (AUC 0.890).Conclusions: Circulating miRNAs are differentially expressed among relapsed and non-relapsed patients with early breast cancer and predict recurrence many years before its clinical detection. Our results suggest that miRNAs represent potential circulating biomarkers in early breast cancer. 	29996899	2018	Circulating microRNAs in the Early Prediction of Disease Recurrence in Primary Breast Cancer	0	1	1	292
NA	NA	NA	NA	hsa-miR-23b/c	qRT-PCR,etc.	up	Results: miR-21 (p < 0.001), miR-23b (p = 0.028) and miR-200c (p < 0.001) expression were higher and miR-190 was lower (p = 0.013) in relapsed (n = 49), compared to non-relapsed patients (n = 84). Interestingly, miR-190 was lower (p = 0.0032) in patients with early relapse (at < 3 years; n = 23) compared to those without early relapse (n = 110). On the other hand, miR-21 and miR-200c were higher (p = 0.015 and p < 0.001, respectively) in patients with late relapse (relapse at  5 years; n = 20) as compared to non-relapsed patients. High miR-200c was associated with shorter disease-free survival (DFS) (p = 0.005) and high miR-21 with both shorter DFS and overall survival (OS) (p < 0.001 and p = 0.033, respectively) compared to low expression. ROC curve analysis revealed that miR-21, miR-23b, miR-190 and miR-200c discriminated relapsed from non-relapsed patients. A combination of of miR-21, miR-23b and miR-190 showed higher sensitivity and specificity in ROC analyses compared to each miRNA alone; accuracy was further improved by adding lymph node infiltration and tumor grade to the panel of three miRs (AUC 0.873). Furthermore, the combination of miR-200c, lymph node infiltration, tumor grade and estrogen receptor predicted late relapse (AUC 0.890).Conclusions: Circulating miRNAs are differentially expressed among relapsed and non-relapsed patients with early breast cancer and predict recurrence many years before its clinical detection. Our results suggest that miRNAs represent potential circulating biomarkers in early breast cancer. 	29996899	2018	Circulating microRNAs in the Early Prediction of Disease Recurrence in Primary Breast Cancer	0	1	1	293
NA	NA	NA	NA	hsa-miR-190 	qRT-PCR,etc.	down	Results: miR-21 (p < 0.001), miR-23b (p = 0.028) and miR-200c (p < 0.001) expression were higher and miR-190 was lower (p = 0.013) in relapsed (n = 49), compared to non-relapsed patients (n = 84). Interestingly, miR-190 was lower (p = 0.0032) in patients with early relapse (at < 3 years; n = 23) compared to those without early relapse (n = 110). On the other hand, miR-21 and miR-200c were higher (p = 0.015 and p < 0.001, respectively) in patients with late relapse (relapse at  5 years; n = 20) as compared to non-relapsed patients. High miR-200c was associated with shorter disease-free survival (DFS) (p = 0.005) and high miR-21 with both shorter DFS and overall survival (OS) (p < 0.001 and p = 0.033, respectively) compared to low expression. ROC curve analysis revealed that miR-21, miR-23b, miR-190 and miR-200c discriminated relapsed from non-relapsed patients. A combination of of miR-21, miR-23b and miR-190 showed higher sensitivity and specificity in ROC analyses compared to each miRNA alone; accuracy was further improved by adding lymph node infiltration and tumor grade to the panel of three miRs (AUC 0.873). Furthermore, the combination of miR-200c, lymph node infiltration, tumor grade and estrogen receptor predicted late relapse (AUC 0.890).Conclusions: Circulating miRNAs are differentially expressed among relapsed and non-relapsed patients with early breast cancer and predict recurrence many years before its clinical detection. Our results suggest that miRNAs represent potential circulating biomarkers in early breast cancer. 	29996899	2018	Circulating microRNAs in the Early Prediction of Disease Recurrence in Primary Breast Cancer	0	1	1	294
chr12	6963699	6963766	MI0000650	hsa-miR-200c 	qRT-PCR,etc.	up	Results: miR-21 (p < 0.001), miR-23b (p = 0.028) and miR-200c (p < 0.001) expression were higher and miR-190 was lower (p = 0.013) in relapsed (n = 49), compared to non-relapsed patients (n = 84). Interestingly, miR-190 was lower (p = 0.0032) in patients with early relapse (at < 3 years; n = 23) compared to those without early relapse (n = 110). On the other hand, miR-21 and miR-200c were higher (p = 0.015 and p < 0.001, respectively) in patients with late relapse (relapse at  5 years; n = 20) as compared to non-relapsed patients. High miR-200c was associated with shorter disease-free survival (DFS) (p = 0.005) and high miR-21 with both shorter DFS and overall survival (OS) (p < 0.001 and p = 0.033, respectively) compared to low expression. ROC curve analysis revealed that miR-21, miR-23b, miR-190 and miR-200c discriminated relapsed from non-relapsed patients. A combination of of miR-21, miR-23b and miR-190 showed higher sensitivity and specificity in ROC analyses compared to each miRNA alone; accuracy was further improved by adding lymph node infiltration and tumor grade to the panel of three miRs (AUC 0.873). Furthermore, the combination of miR-200c, lymph node infiltration, tumor grade and estrogen receptor predicted late relapse (AUC 0.890).Conclusions: Circulating miRNAs are differentially expressed among relapsed and non-relapsed patients with early breast cancer and predict recurrence many years before its clinical detection. Our results suggest that miRNAs represent potential circulating biomarkers in early breast cancer. 	29996899	2018	Circulating microRNAs in the Early Prediction of Disease Recurrence in Primary Breast Cancer	0	1	1	295
